



EXPRESS MAIL NO. EV335393045US

6-30-04

1632

**TRANSMITTAL
FORM**(To be used for all correspondence
after initial filing)

Application Number	10/007,700
Filing Date	November 30, 2001
First Named Inventor	Tongtong Wang
Art Unit	1632
Examiner Name	Shin-Lin Chen, Ph.D.
Attorney Docket No.	210121.455C17

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Fourth Supplemental Information Disclosure Statement; Form PTO-1449 (7 Sheets)	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> 77 Cited References	<input type="checkbox"/> Terminal Disclaimer	_____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	_____
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		_____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		_____

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461	Customer Number 00500
Signature		
Date	June 28, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name		
Signature		Date:

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1476030

FEE TRANSMITTAL
for FY 2004

Patent fees are subject to annual revision.

☐ Claims small entity status. See 37 CFR 1.27.

TOTAL AMOUNT OF PAYMENT (\$) **180.00**

Complete if Known

Application Number	10/007,700
Filing Date	November 30, 2001
First Named Inventor	Tongtong Wang
Examiner Name	Shin-Lin Chen, Ph.D.
Art Unit	1632
Attorney Docket No.	210121.455C17

METHOD OF PAYMENT

☒ Payment Enclosed:
☒ Check ☐ Credit card ☐ Money Order ☐ Other

☐ Deposit Account:
 Deposit Account Number: **19-1090**
 Deposit Account Name: **Seed Intellectual Property Law Group PLLC**

The Director is authorized to (check all that apply):
☐ Charge fee(s) indicated below ☒ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any deficiencies
 to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims			
Multiple Dependent			

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)				

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2520	1812	2520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1480	2254	740	Extension for reply within fourth month	
1255	2010	2255	1005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1510	1451	1510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1330	2453	665	Petition to revive - unintentional	
1501	1330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify) _____					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3) (\$)					180.00

SUBMITTED BY				Customer Number	
Name (Print/Type)	Julie A. Urvater, Ph.D., Patent Agent	Registration No. Attorney/Agent	50,461	00500	
Signature	<i>Julie Urvater</i>	Date	June 28, 2004		

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXPRESS MAIL NO. EV335393045US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tongtong Wang et al.
Application No. : 10/007,700
Filed : November 30, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF LUNG CANCER

Examiner : Shin-Lin Chen, Ph.D.
Art Unit : 1632
Docket No. : 210121.455C17
Date : June 28, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

07/02/2004 MBERHE 00000148 10007700

01 FC:1806


180.00 0P

Please acknowledge receipt of this Fourth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:ljt

Enclosures:

Postcard
Check for \$180
Transmittal Form
Fee Transmittal Form (+1)
Forms PTO-1449 (7 Sheets)
Cited References (77)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

V476031

FORM PTO-1449
(REV.7-80)

JUN 28 2004

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C17

APPLICATION NO.

10/007,700

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tongtong Wang et al.

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AC	EP 679716 A1	11/02/95	EPO		
	AD	EP 1033401 A2	09/06/00	EPO		
	AE	EP 1130094 A2	09/05/01	EPO		
	AF	WO 99/46594	09/16/99	WIPO		
	AG	WO 01/47944	07/05/01	WIPO		
	AH	WO 01/55322	08/02/01	WIPO		
	AI	WO 01/57272	08/09/01	WIPO		
	AJ	WO 01/57275	08/09/01	WIPO		
	AK	WO 01/57276	08/09/01	WIPO		
	AL	WO 01/57277	08/09/01	WIPO		
	AM	WO 01/75067	10/11/01	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AN	GenBank Database, Accession No. AAB82295, October 30, 1997.
	AO	GenBank Database, Accession No. AAB97457, January 22, 1998.
	AP	GenBank Database, Accession No. AAC18597, June 3, 1998.
	AQ	GenBank Database, Accession No. AAC18598, June 3, 1998.
	AR	GenBank Database, Accession No. AAC35208, May 13, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C17

APPLICATION NO.

10/007,700

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tongtong Wang et al.

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					


OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

BC	GenBank Database, Accession No. AAC41285, May 13, 1998.
BD	GenBank Database, Accession No. AAC65900, October 10, 2003.
BE	GenBank Database, Accession No. AAD09223, January 26, 1999.
BF	GenBank Database, Accession No. AAD09827, January 26, 1999.
BG	GenBank Database, Accession No. AAD09828, January 26, 1999.
BH	GenBank Database, Accession No. AAF37203, March 2, 2000.
BI	GenBank Database, Accession No. AC005082, September 8, 1999.
BJ	GenBank Database, Accession No. AC021876, January 21, 2000.
BK	GenBank Database, Accession No. AC079780, February 21, 2002.
BL	GenBank Database, Accession No. AC092447, July 4, 2001.
BM	GenBank Database, Accession No. AF117108, January 26, 1999.
BN	GenBank Database, Accession No. AF198254, March 2, 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700	
 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Tongtong Wang et al.			
				FILING DATE November 30, 2001		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	CB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CC	GenBank Database, Accession No. AL023775, November 23, 1999.					
	CD	GenBank Database, Accession No. BAB19755, December 20, 2000.					
	CE	GenBank Database, Accession No. BAB27779, February 8, 2001.					
	CF	GenBank Database, Accession No. BAB27848, February 8, 2001.					
	CG	GenBank Database, Accession No. BC019258, December 19, 2001.					
	CH	GenBank Database, Accession No. O00425, July 1, 1997.					
	CI	GenBank Database, Accession No. NM_006547, November 1, 2000.					
	CJ	GenBank Database, Accession No. NP_034081, January 25, 2000.					
	CK	GenBank Database, Accession No. NP_006537, August 10, 1999.					
	CL	GenBank Database, Accession No. NP_006538, November 1, 2000.					
	CM	GenBank Database, Accession No. NP_006539, August 10, 1999.					
	CN	GenBank Database, Accession No. NP_571566, February 20, 2002.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							


FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C17

APPLICATION NO.

10/007,700

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tongtong Wang et al.

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					


OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*


DC	GenBank Database, Accession No. NP_076159, February 19, 2001.
DD	GenBank Database, Accession No. U76705, January 26, 1999.
DE	GenBank Database, Accession No. U97188, May 20, 1997.
DF	GenBank Database, Accession No. XM_004780, November 16, 2000.
DG	GenBank Database, Accession No. XP_004780, November 16, 2000.
DH	Geneseq Database (Thomson Derwent), Accession AAL28189, January 24, 2002.
DI	Geneseq Database (Thomson Derwent), Accession AAM93826, November 6, 2001.
DJ	Geneseq Database (Thomson Derwent), Accession AAT26750, October 23, 1996.
DK	Geneseq Database (Thomson Derwent), Accession AAU16161, November 7, 2001.
DL	Geneseq Database (Thomson Derwent), Accession AAU16163, November 7, 2001.
DM	Geneseq Database (Thomson Derwent), Accession AAU16164, November 7, 2001.
DN	Geneseq Database (Thomson Derwent), Accession AAU16166, November 7, 2001.
DO	Geneseq Database (Thomson Derwent), Accession AAU16579, November 7, 2001.
DP	Geneseq Database (Thomson Derwent), Accession AAU16583, November 7, 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700	
 <p>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>				APPLICANTS Tongtong Wang et al.			
				FILING DATE November 30, 2001		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	EB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	EC		Ackermann, R. "Monoclonal antibodies," <i>Human Cell</i> 1(1): 46-53, 1988 (Abstract Only; PubMed ID:3154013).				
	ED		Arceci, R.J., "The potential for antitumor vaccination in acute myelogenous leukemia," <i>J. Mol. Med.</i> 76: 80-93, 1998.				
	EE		Bergers and Coussens, "Extrinsic regulators of epithelial tumor progression: metalloproteinases," <i>Current Opinion in Genetics & Developments</i> 10: 120-127, 2000.				
	EF		Bodey, B. et al., "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Research</i> 20: 2665-2676, 2000.				
	EG		Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," <i>Advances in Cancer Research</i> 58: 177-210, 1992.				
	EH		Eck and Wilson, "Gene-Based Therapy," in <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th Edition, McGraw-Hill, New York, 1996, pgs. 77-101.				
	EI		Ezzell, C., "Cancer 'Vaccines': An Idea Whose Time Has Come?" <i>The Journal of NIH Research</i> 7: 46-49, January 1995.				
	EJ		Greenspan and Cooper, "Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions," <i>Immunology Today</i> 16(5): 226-230, 1995.				
	EK		Gura, T., "System for Identifying New Drugs Are Often Faulty," <i>Science</i> 278: 1041-1042, November 7, 1997.				
	EL		Kaye, F.J. et al. "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding," <i>Proc. Natl. Acad. Sci. USA</i> 87: 6922-6926, September 1990.				
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

FOURTH SUPPLEMENTAL INFORMATIONAL DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO.

210121.455C17

APPLICATION NO.

10/007,700

APPLICANTS

Tongtong Wang et al.

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FB					


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FC	Lee, K-H. et al., "Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression," <i>The Journal of Immunology</i> 163: 6292-6300, 1999.
FD	Müller-Pillasch, F. et al., "Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein," <i>Oncogene</i> 14: 2729-2733, 1997.
FE	New England Biolabs website, Description on the pCyB Expression Vectors: http://circuit.neb.com/neb/faqs/impact2.html , (2001)
FF	Nielsen, J. et al., "A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development," <i>Molecular and Cellular Biology</i> 19(2): 1262-1270, February 1999.
FG	Radoja and Frey, "Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing," <i>Molecular Medicine</i> 6(6): 465-479, June 2000.
FH	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , Parsons, J.A. (ed.), University Park Press, Baltimore MD, June 1976, pgs. 1-7
FI	Sjölander, A. et al., "Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins," <i>Vaccine</i> 15(9): 1030-1038, 1997.
FJ	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotechnology</i> 18: 34-39, January 2000.
FK	Spitler, L.E., "Cancer Vaccines: The Interferon Analogy," <i>Cancer Biotherapy</i> 10(1): 1-3, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEFOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

210121.455C17

APPLICATION NO.

10/007,700

APPLICANTS

Tongtong Wang et al.

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GC		Stern, P.S., "Predicting antigenic sites on proteins," <i>Trends in Biotechnology</i> 9: 163-169, May 1991.
	GD		Timmerman and Levy, "Dendritic Cell Vaccines for Cancer Immunotherapy," <i>Annu. Rev. Med.</i> 50: 507-529, 1999.
	GE		Wong, C.P. et al., "TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8 ⁺ T Cell Response," <i>The Journal of Immunology</i> 162: 2251-2258, 1999.
	GF		Zaks and Rosenberg, "Immunization with Peptide Epitope (p369-377) from HER-2/neu Leads to Peptide-specific Cytotoxic T Lymphocytes That Fail to Recognize HER-2/neu+ Tumors," <i>Cancer Research</i> 58: 4902-4908, November 1, 1998.
	GG		
	GH		
	GI		
	GJ		
	GK		
	GL		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).